Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center

Main Article Content

Adnan Al Shaikh
Hadeer Daftardar
Abdul Aziz Alghamdi
Majd Jamjoom
Saniah Awidah
Mohamed E Ahmed
Ashraf T Soliman

Keywords

linear growth, HtSDS, GH deficiency (GHD), idiopathic short stature (ISS), small for gestational age (SGA), Turner syndrome (TS), recombinant GH therapy (rhGH)

Abstract

Objectives: To assess the long-term effect of growth hormone (GH) therapy in a large cohort of short children with different etiologies. Patients and Methods: We evaluated retrospectively the anthropometric data of 252 short children [height SDS <-2: 154 children with growth hormone deficiency (GHD), 63 with idiopathic short stature (ISS), 26 with SGA, and 9 with Turner syndrome (TS)] who were treated, in our center, with GH between 1-2007 and 1-2018. Before and during recombinamt growth-hormone (recGH) treatment, auxological parameters including height (Ht), weight (Wt), Ht - Z score (HtSDS), body mass index (BMI) and BMISDS were recorded every 6 months; bone age (BA) was assessed every 12 months. Results: At the end of first year of rhGH therapy and after an average of 3 years treatment all groups of short children had significant increase in HtSDS, which was higher in GHD compared to other groups. Children with GHD, SGA, ISS and TS increased their HtSDS by an average of 2.2, 1.46, 0.6 and 0.99 SD, respectively at the end of follow up period (for all groups, p: <0.001). The bone age/chronological age (BA/CA) ratio did not differ significantly among ISS, GHD and SGA groups after GH therapy. The HtSDS gain was higher in children with GHD compared to other ISS, SGA and TS groups (p:< 0.01; p: 0.015 and p: 0.029, respectively).  HtSDS improvement occurred during the first 3 years of rhGH therapy. The BMISDS increased significantly in children with GHD, after 3 years of rhGH therapy (p: < 0.001). After rhGH treatment, the BMISDS decreased significantly in children with ISS and SGA (p: < 0.01 and < 0.001, respectively) but did not change in children with TS (p: 0.199). Conclusions: Children with GHD, SGA, ISS and TS exhibited significant increases in HtSDS when treated with rhGH for 3 years. The HtSDS gain was higher in children with GHD compared to other groups.

a

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 253 | PDF Downloads 133

References

1. Grimberg A, Allen DB. Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence. Curr Opin Pediatr. 2017;29:466–471.
2. Ranke MB. Towards a consensus on the definition of idiopathic short stature. Horm Res. 1996;45(Suppl 2):64–66.


3. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM; 2007 ISS Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93:4210–4217.
4. Loche S, Carta L, Ibba A, Guzzetti C. Growth hormone treatment in non-growth hormone-deficient children. Ann Pediatr Endocrinol Metab. 2014; 19:1–7.
5. Gubitosi-Klug RA, Cuttler L. Idiopathic short stature. Endocrinol Metab Clin North Am. 2005; 34:565–580.
6. Hwang IT. Efficacy and safety of growth hormone treatment for children born small for gestational age. Korean J Pediatr. 2014;57:379–383.
7. Rapaport R, Lee P, Ross J, Saenger P, Ostrow V, Piccoli G. Growth hormone therapy in children born small for gestational age: results from the ANSWER program. Endocr Connect. 2018 Aug 23. pii: EC-18-0286. doi: 10.1530/EC-18-0286
8. Van den Broeck J, Massa GG, Attanasio A, Matranga A, Chaussain JL, Price DA, Aarskog D, Wit JM. Final height after long-term growth hormone treatment in Turner syndrome. European Study Group. J Pediatr. 1995; 127:729–735.
9. Li P, Cheng F, Xiu L. Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis. Endocr Connect. 2018;7:573-583.
10. Takeda A1, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, Welch K, Bryant J. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1-209.
11. Wit JM1, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P. Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res. 2008;18:89-110.
12. de Onis M., Habicht J.P. Anthropometric reference data for international use: recommendations from a World Health Organization Expert Committee. Am J Clin Nutr. 1996;64:650–658.
13. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452.
14. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85:3990–3993.
15. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Frasier SD, Hasegawa Y, Hintz RL, Lafranchi S, Lippe B, Loriaux L, Melmed S. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab. 1995;80:1532–1540.
16. Cui X, Cui Y, Shi L, Luan J, Zhou X, Han J. A basic understanding of Turner syndrome: Incidence, complications, diagnosis, and treatment. Intractable Rare Dis Res. 2018;7:223–228.


17. Galluzzi F, Stagi S, Parpagnoli M, Losi S, Pagnini I, Favelli F, Chiarelli F, Salti R, Seminara S. Oral clonidine provocative test in the diagnosis of growth hormone deficiency in childhood: should we make the timing uniform? Horm Res. 2006;66:285-288.
18. Gillis D, Magiel E, Terespolsky N, Naugolny L, Strich D. CLONIDINE STIMULATION TEST FOR GH DEFICIENCY: A NEW LOOK AT SAMPLE TIMING. Endocr Pract.2016 ;22:338-342.
19. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85:3990–3993
20. Strich D1, Terespolsky N, Gillis D. Glucagon stimulation test for childhood growth hormone deficiency: timing of the peak is important. J Pediatr. 2009;154:415-419.
21. Banerjee I, Clayton PE. Clinical utility of insulin-like growth factor-I (IGF-I) and IGF binding protein-3 measurements in paediatric practice. Pediatr Endocrinol Rev. 2006;3:393-402.
22. Savage MO, Bang P. The variability of responses to growth hormone therapy in children with short stature. Indian J Endocrinol Metab. 2012;16 (Suppl 2):S178–S184.
23. Rachmiel M, Rota V, Atenafu E, Daneman D, Hamilton J. Final height in children with idiopathic growth hormone deficiency treated with a fixed dose of recombinant growth hormone. Horm Res. 2007;68:236–243.
24. Albertsson-Wikland K, Aronson AS, Gustafsson J, Hagenäs L, Ivarsson SA, Jonsson B, Ritzén M, Tuvemo T, Westgren U, Westphal O, Aman J. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab. 2008;93:4342–4350.
25. Dahlgren J, Wikland KA Swedish Study Group for Growth Hormone Treatment. Final height in short children born small for gestational age treated with growth hormone. Pediatr Res. 2005; 57:216–222.
26. Cohen P, Weng W, Rogol AD, Rosenfeld RG, Kappelgaard AM, Germak J. Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Clin Endocrinol (Oxf). 2014;81:71-76.
27. Liu HJ1, Wang LH2, Chen L.Evaluation of Safety and Efficacy of Growth Hormone Therapy by IGF-1 Z Score in Children with Short Stature. Adv Ther. 2019;36:2374-2383.
28. Lee BC, Lee SJ, Jung MH. Final height in growth hormone deficient children treated with growth hormone. J Korean Soc Pediatr Endocrinol. 2003;8:27–33.
29. Choi IJ, Hwang JS, Shin CH, Yang SW. Factors affecting on final adult height and total height gain in children with idiopathic and organic growth hormone deficiency after growth hormone treatment. J Korean Pediatr Soc. 2003;46:803–810.
30. Kim DH, Shin HJ, Chung SC, Park MJ. Response of growth hormone treatment to final height in children with growth hormone deficiency and familial short stature. J Korean Soc Pediatr Endocrinol. 1999;4:159–169.
31. Kim SA, Choe YR, Yang EM, Kim CJ. Comparison of growth hormone treatment in patients with idiopathic short stature and idiopathic growth hormone deficiency. Chonnam Med J. 2014;50:63–66.
32. Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, Crowe BJ, Ross JL, Cassorla FG, Blum WF, Cutler GB Jr, Baron J; National Institute of Child Health and Human Development-Eli Lilly & Co. Growth Hormone Collaborative Group. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89:3140–3148.
33. McCaughey ES, Mulligan J, Voss LD, Betts PR. Randomised trial of growth hormone in short normal girls. Lancet. 1998;351:940–944.
34. Kang JC, Choi YS, Choi IK, Kim HS, Kim DH. The effect of growth hormone on patients with growth hormone deficiency and idiopathic short stature. Korean J Pediatr. 2004;47:310–318.
35. Sotos JF, Tokar NJ. Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit. Int J Pediatr Endocrinol. 2014; 2014:15. doi: 10.1186/1687-9856-2014-15.
36. Gubitosi-Klug RA, Cuttler L. Idiopathic short stature. Endocrinol Metab Clin North Am. 2005; 34:565–580.
37. Park P, Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res. 2004;62 (Suppl 1):59–65.
38. Cohen P, Weng W, Rogol AD, Rosenfeld RG, Kappelgaard AM, Germak J. Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Clin Endocrinol (Oxf) 2014; 81:71–76.
39. Clayton P, Cianfarani S, Czernichow G, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society, J Clin Endocrinol Metab. 2007;92:804–810.
40. De Zegher F, Francois I, van Helvoirt M, Van den Berghe G. Small as fetus and short as child: from endogenous to exogenous growth hormone, J Clin Endocrinol Metab, 1997;82:2021–2016.
41. Hofman PL, Cutfield WS, Robinson EW, Bergman RN, Menon RK, Sperling MA, Gluckman PD. Insulin resistance in short children with intrauterine growth retardation, J Clin Endocrinol Metab. 1997;402–406.


42. Hales CN, Barker DJP. The thrifty phenotype hypothesis. Br Med Bull. 2001;60;5–20.
43. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P; International Small for Gestational Age Advisory Board. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age. Pediatrics. 2003;111:1253-1261
44. Johnston LB, Savage MO. Should recombinant human growth hormone therapy be used in short small for gestational age children? Arch Dis Child. 2004;89:740-744.
45. Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Adult height alter long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial, J Clin Endocrinol Metab. 2003;88:3584–3590.
46. Dahlgren J, Albertsson Wikland K. Final height in short children born small for gestational age treated with growth hormone, Pediatr Res. 2005;57:216–222.
47. Carel JC, Chatelain P, Rochiccioli P, Chaussain JL. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study, J Clin Endocrinol Metab, 2003;88:1587–1593.
48. Maiorana A, Cianfarani S. Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics, 2009;124:519–531.
49. Klein ML, Robert Rapaport R. Growth hormone treatment in children born small for gestational age— adult height and metabolic consequences. US Endocrinology, 2010;6:63-70.
50. Rogol AD, Richmond EJ. Eds: Geffner ME, Hoppin AG. https://www.uptodate.com /contents/growth-hormone-treatment-for-children-born-small-for-gestational-age
51. Ranke MB, Pflüger H, Rosendahl W, Stubbe P, Enders H, Bierich JR, Majewski F. Eur Turner syndrome: spontaneous growth in 150 cases and review of the literature. J Pediatr. 1983;141:81-88.
52. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Söderström-Anttila V, Stochholm K, van Alfen-van derVelden JA, Woelfle J, Backeljauw PF, International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017;177: G1-G70.
53. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab. 1999; 84:4607-4612.



54. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, RouwéCW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003;88:1119-1125.
55. Reiter EO, Blethen SL, Baptista J, Price L. Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner's syndrome. J Clin Endocrinol Metab. 2001;86:1936-1941.
56. Davenport ML, Roush J, Liu C, Zagar AJ, Eugster E, Travers S, Fechner PY, Quigley CA. Growth hormone treatment does not affect incidences of middle ear disease or hearing loss in infants and toddlers with Turner syndrome. Horm Res Paediatr. 2010;74:23-32.
57. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017 ; 177:G1-G70.
58. Saenger P. Growth-promoting strategies in Turner's syndrome. J Clin Endocrinol Metab. 1999;84:4345.
59. Sas TC, Cromme-Dijkhuis AH, de Muinck Keizer-Schrama SM, et al. The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner's syndrome. Dutch Working Group on Growth Hormone. J Pediatr 1999; 135:470.
60. Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in turner syndrome. J Clin Endocrinol Metab. 2008;93:344-348.